Time on Treatment Analysis
(All Subjects)
Placebo
Xanomeline High Dose
Placebo vs.
Xanomeline High
Dose
N
Numbe
r of
Events
(%)
Estimat
ed
Median
Time
(95%C
I) in
Months
N
Numbe
r of
Events
(%)
Estimat
ed
Median
Time
(95%C
I) in
Months
Hazard
Ratio
(95%C
I)
P-value
Time to First
Dermatologic
al Event
86
29
(33.7)
NA
(NA,N
A)
84
61
(72.6)
1.2
(0.8,1.5
)
4.92
(3.08,7.
85)
<0.001
NOTE: N in column headers represents number of subjects entered in study (i.e., signed informed consent).
